STOCK TITAN

InMed Pharmaceuticals Inc. Common Shares - INM STOCK NEWS

Welcome to our dedicated page for InMed Pharmaceuticals Common Shares news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals Common Shares stock.

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a leading Canadian clinical-stage biopharmaceutical company at the forefront of cannabinoid research and development. Specializing in the creation of novel therapies, InMed harnesses the extensive pharmacology of cannabinoids, combined with cutting-edge drug delivery systems.

InMed's innovative approach includes a robust product pipeline featuring:

  • INM-755: A topical cream for the treatment of epidermolysis bullosa, a rare skin condition.
  • INM-088: An ophthalmic formulation targeting glaucoma to preserve retinal function.
  • INM-901: A promising treatment for Alzheimer's disease, showing multiple mechanisms of action to improve cognitive and memory functions.
  • INM-089: Aimed at treating age-related macular degeneration (AMD), focusing on retinal protection and functionality.

The company's proprietary IntegraSyn manufacturing system ensures the production of high-quality pharmaceutical-grade cannabinoids, positioning them as a key player in the industry.

InMed's recent achievements include:

  • Completion of a Phase 2 clinical trial for INM-755.
  • Initiation of two new preclinical programs for Alzheimer's and AMD.
  • Strong financial performance with significant revenue growth from its subsidiary BayMedica, which supplies rare cannabinoids to the health and wellness sector.

InMed's commitment to advancing cannabinoid science is evident through its strategic partnerships, rigorous research, and innovative product development, making significant strides in treating diseases with high unmet medical needs. For more information, visit www.inmedpharma.com.

Rhea-AI Summary

InMed Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully closed a private placement raising approximately US$4.0 million. A total of 1,050,000 units were sold at US$4.25 per unit, each unit comprising one common share and 0.66 of a warrant. The warrants have an exercise price of US$4.85 and are exercisable six months post-issuance. InMed will use the proceeds for working capital. The securities issued will not be registered under the Securities Act, and InMed is set to file a registration statement with the SEC within 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
none
-
Rhea-AI Summary

InMed Pharmaceuticals reported its fiscal Q2 2021 financial results, highlighting a net loss of $2.2 million, down from $2.5 million a year ago. The company achieved significant milestones for its INM-755 program, targeting Epidermolysis Bullosa, demonstrating safety and tolerability in Phase 1 trials. Cash reserves improved to $10.1 million, up from $4.5 million in September 2020, following an $8 million public offering. InMed also entered a licensing agreement for ocular drug delivery technology aimed at glaucoma treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
-
Rhea-AI Summary

InMed Pharmaceuticals reported its second quarter fiscal 2021 financial results, ending December 31, 2020. The company achieved critical milestones in its drug development, particularly for INM-755 aimed at Epidermolysis Bullosa, with upcoming Phase 2 trials planned. It secured a worldwide license for ocular drug delivery technology, MiDROPS®, enhancing its research pipeline. Financially, InMed raised about $12.5 million through recent offerings and recorded a net loss of $2.2 million in Q2 2021, an improvement from $2.5 million in Q2 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.15%
Tags
Rhea-AI Summary

InMed Pharmaceuticals Inc. (NASDAQ: INM) will report its financial results for the second quarter of fiscal year 2021, ending December 31, 2020, on February 11, 2021. A conference call and webcast will occur at 8:30 AM Pacific Time. The company is focused on developing cannabinoid-based medications, particularly targeting the therapeutic benefits of cannabinol (CBN). Full financial statements will be accessible on their website and regulatory authorities after the announcement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
conferences earnings
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (NASDAQ: INM), a clinical-stage pharmaceutical company, is set to report its financial results for Q2 of fiscal year 2021 on February 11, 2021. The company focuses on developing cannabinoid-based medications, specifically cannabinol (CBN) for diseases with high unmet medical needs. A conference call and webcast will take place on the same day at 8:30 AM PT with details available on their website. InMed emphasizes its commitment to delivering therapeutic alternatives while navigating the uncertainties inherent in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.69%
Tags
conferences earnings
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. announced a private placement to raise approximately US$4.5 million, issuing units at US$4.25 per share. Each unit consists of one common share and 0.66 warrants with an exercise price of US$4.85. The expected net proceeds are about US$4.0 million, intended for working capital. The offering is expected to close around February 12, 2021, pending regulatory approval. Roth Capital Partners is the placement agent, and InMed will file a registration statement for resales within 30 days post-closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.39%
Tags
none
Rhea-AI Summary

InMed Pharmaceuticals Inc. announced a private placement to raise approximately US$4.5 million at US$4.25 per unit, with each unit consisting of one common share and 0.66 warrant. The exercise price for the warrants is set at US$4.85, with an expected close date of February 12, 2021. After fees, net proceeds are anticipated to be around US$4.0 million for working capital. Roth Capital Partners acted as the exclusive placement agent. The announcement includes forward-looking statements regarding regulatory approvals and the potential success of its cannabinoid-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.39%
Tags
none
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (NASDAQ:INM) announced participation in the virtual 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe from January 19-21, 2021. Key executives, including Michael Woudenberg, Karen Long, and Prof. Mauro Maccarrone, will share insights on cannabinoid therapeutics. Woudenberg will discuss the comparison of whole plant and synthetic cannabinoids, while Long will focus on drug approval processes. Maccarrone will address endocannabinoid signaling in his lecture. CEO Eric A. Adams highlighted the company's progress in therapeutic development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
conferences
-
Rhea-AI Summary

InMed Pharmaceuticals Inc. (NASDAQ: INM, TSX: IN) announced promising top-line results from its 755-102-HV Phase 1 clinical trial evaluating INM-755 cream for treating epidermolysis bullosa. The trial, involving 8 healthy volunteers, demonstrated that the cream was safe and well-tolerated, with no significant adverse effects noted. Notably, the cream did not impede normal wound healing. Following this success, InMed is preparing to file regulatory applications for a Phase 2 efficacy and safety study in multiple countries within the first half of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
Rhea-AI Summary

InMed Pharmaceuticals (NASDAQ: INM) will participate in several virtual investor and partnering conferences in January 2021. Key events include the H.C. Wainwright BioConnect Conference from January 11-14, where a presentation by CEO Eric A. Adams will be available on demand. Additionally, the BIO Partnering at JPM will occur January 11-15, with registration options available. The Edison Open House: Global Healthcare 2021 is set for January 26-28. InMed focuses on developing cannabinoid-based medications for diseases with significant unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
conferences

FAQ

What is the current stock price of InMed Pharmaceuticals Common Shares (INM)?

The current stock price of InMed Pharmaceuticals Common Shares (INM) is $4.68 as of December 23, 2024.

What is the market cap of InMed Pharmaceuticals Common Shares (INM)?

The market cap of InMed Pharmaceuticals Common Shares (INM) is approximately 3.2M.

What is InMed Pharmaceuticals Inc.?

InMed Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in the research, development, and manufacturing of novel cannabinoid-based therapies.

What products are in InMed's pipeline?

InMed's product pipeline includes INM-755 for epidermolysis bullosa, INM-088 for glaucoma, INM-901 for Alzheimer's disease, and INM-089 for age-related macular degeneration.

What is the IntegraSyn manufacturing system?

IntegraSyn is InMed's proprietary manufacturing system designed to produce high-quality pharmaceutical-grade cannabinoids efficiently.

What recent achievements has InMed made?

Recent achievements include completing a Phase 2 clinical trial for INM-755, launching preclinical programs for Alzheimer's and AMD, and significant revenue growth from BayMedica.

Who are InMed's strategic partners?

InMed collaborates with various pharmaceutical and biotechnology companies to advance its cannabinoid research and development efforts.

What financial outlook does InMed have?

InMed has shown strong financial performance, with revenue growth from its subsidiary BayMedica and a solid cash position to support its ongoing operations.

What diseases does InMed target?

InMed targets diseases with high unmet medical needs, including epidermolysis bullosa, glaucoma, Alzheimer's disease, and age-related macular degeneration.

How does InMed contribute to the health and wellness industry?

Through its subsidiary BayMedica, InMed supplies rare cannabinoids to brands within the health and wellness industry, driving revenue growth and expanding market reach.

Where can I find more information about InMed?

For more information, visit InMed's websites at www.inmedpharma.com and www.baymedica.com.

What are the future plans for InMed's product development?

InMed plans to further develop its proprietary small molecule drug candidates, continue preclinical and clinical trials, and explore new therapeutic areas.

InMed Pharmaceuticals Inc. Common Shares

OTC:INM

INM Rankings

INM Stock Data

3.16M
713.96k
0.87%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
VANCOUVER